Insight Molecular Diagnostics Inc. Common Stock IMDX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$4.29M+35.7% | -$22.96M+31.5% | -$10.85M+19.6% | -$9.74M-115% | -$6.67M+26.9% | ||
| $631K+30.4% | $563K+4.1% | $584K+83.6% | $559K+83.9% | $484K+54.6% | ||
| $615K+30.0% | $721K+44.5% | $521K+15.8% | $504K+30.6% | $473K+13.2% | ||
| -$971K-150% | —— | -$254K-305% | -$3.03M-3,884% | $1.93M+697% | ||
| -$64K-231% | —— | —— | $234K— | $49K— | ||
| -$105K-110% | $3.56M+405% | $1.18M+81.4% | -$3.11M-151% | $1.03M+20.3% | ||
| -$449K-628% | $102K+32.5% | —— | $104K— | $85K+37.1% | ||
| $0-100% | $14.59M-65.1% | $0-100% | $0-100% | $7K-68.2% | ||
| -$83K-177% | -$20K+88.1% | -$57K— | -$35K-29.6% | -$30K+68.8% | ||
| -$5.92M-773% | —— | $3.38M-52.7% | $2.8M+372% | $879K-73.5% | ||
| -$7.64M-30.8% | -$5.55M-3.6% | -$4.5M+18.6% | -$6.3M-5.4% | -$5.84M-52.5% | ||
| $613K+99.7% | $1.48M+591% | $1.05M+1,107% | $349K+82.7% | $307K+1,179% | ||
| -$613K-99.7% | -$1.48M-604% | -$1.05M-1,107% | -$349K-82.7% | -$307K-1,179% | ||
| $26.02M-10.7% | —— | —— | —— | $29.14M— | ||
| —— | $18K— | $18K— | $18K— | $18K— | ||
| —— | $500— | $500— | $500— | $500— | ||
| $24.7M-13.5% | —— | —— | —— | $28.56M— | ||
| -$10K+47.4% | -$15K-400% | —— | —— | -$19K— | ||
| $16.44M-26.6% | —— | —— | —— | $22.39M+681% | ||
| $19K-20.8% | $22K-12.0% | $24K+41.2% | $21K— | $24K— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0-100% | $0-100% | $0-100% | $0-100% | $7K-68.2% | ||
| -$5.92M-773% | —— | $3.38M-52.7% | $2.8M+372% | $879K-73.5% | ||
| $32K+129% | $38K-24.0% | $38K+171% | $74K— | $14K— | ||
| $5K+113% | -$15K-145% | —— | —— | -$39K— | ||
| -$83K-177% | -$20K+88.1% | -$57K— | -$35K-29.6% | -$30K+68.8% | ||
| -$449K-628% | $102K+32.5% | —— | $104K— | $85K+37.1% | ||
| $1.18M+143% | —— | —— | —— | $487K— | ||
| $143K+45.9% | $178K+117% | $120K+39.5% | $114K— | $98K— | ||
| -$10K+47.4% | -$15K-400% | —— | —— | -$19K— | ||
| $196K— | —— | —— | —— | $0— | ||
| -$83K-177% | -$20K+88.1% | -$57K— | -$35K-29.6% | -$30K+68.8% | ||
| $0-100% | $765K— | $99K-81.6% | $185K-63.3% | $89K-88.1% | ||
| $485K-54.5% | $1.28M+375% | —— | —— | $1.07M— | ||
| —— | $500— | $500— | $500— | $500— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$8.25M-34.3% | -$7.02M-26.2% | -$5.55M+1.2% | -$6.65M-7.7% | -$6.15M-59.5% | ||
| -$8.25M-34.3% | -$7.02M-26.2% | -$5.55M+1.2% | -$6.65M-7.7% | -$6.15M-59.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Insight Molecular Diagnostics Inc. Common Stock generate?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated -$24.0M in operating cash flow over the trailing twelve months.
- What is Insight Molecular Diagnostics Inc. Common Stock's free cash flow?
- After $3.5M of capital expenditures, Insight Molecular Diagnostics Inc. Common Stock's free cash flow was -$27.5M over the trailing twelve months, down 16.9% year over year.
- Where does Insight Molecular Diagnostics Inc. Common Stock's cash flow data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
